Pinnacle Associates 13F: New $2.3M Stake in Disc Medicine (IRON)

Pinnacle Associates opened a new position in Disc Medicine, Inc. (NASDAQ:IRON), purchasing 35,291 shares valued at about $2.31 million. The investment was revealed in a Form 13F filing submitted to the Securities and Exchange Commission on October 20, 2026.

IRON Disc Medicine, Inc.

$76 ▼ -3.91% year to date

1M 3M YTD

Daily close · Oct 21, 2026

What Changed in Pinnacle Associates's Disc Medicine Position

Pinnacle Associates established its stake during the period, bringing onto its books 35,291 shares of the biotechnology company. Because this was a brand-new holding, the firm had no prior shares of the company in the previous period. The reported value of the investment reached $2,310,149 as of the filing date.

Other Institutional Activity in Disc Medicine

RA Capital Management, L.P. held 2,450,221 shares worth about $186,216,796 with no change in its share count. Vestal Point Capital, LP grew its holdings by 850,005 shares, ending with 1,550,000 shares worth about $117,800,000, which works out to a 121.4% increase. Atlas Venture Life Science Advisors, LLC held 1,513,875 shares valued at about $115,054,500 with no change in its position.

Disc Medicine, Inc. Stock Down 2.7%

Disc Medicine shares closed at $79.48 on October 20, 2026, and recently traded around that same price of $79.48 as of October 22, 2026. The stock sits about 11.1% above its 50-day moving average of $71.57 and about 12.5% above its 200-day moving average of $70.66. Shares trade roughly 20.1% below their 52-week high of $99.50 while holding well above their 52-week low of $40.00.

Recent Earnings

Disc Medicine reported a trailing-twelve-month earnings per share of -$6.58 alongside a net margin of 0.0% and a return on equity of -39.1%. The company is scheduled to release its next financial results on November 5, 2026.

Insider Buying and Selling at Disc Medicine, Inc.

Chief Legal Officer Rahul Khara sold 1,649 shares at an average price of $75.00 on June 29, 2026, for a total of $123,675 under a Rule 10b5-1 plan, and separately acquired 1,649 shares at $14.69 on the same day. Director Kevin Bitterman sold 10,994 shares at $79.97 on October 19, 2026, for $879,190.18 under a planned arrangement, and later sold 5,312 shares at $79.95 on October 20, 2026, for $424,694.40.

Analysts Set New Price Targets

BMO Capital maintained an outperform rating on October 19, 2026, raising its price target to $120.00 from $100.00. Morgan Stanley maintained an overweight rating on October 20, 2026, lifting its target to $92.00 from $90.00. Truist Securities maintained a buy rating on October 20, 2026, increasing its target to $115.00 from $83.00. Wells Fargo maintained an overweight rating on October 20, 2026, raising its target to $124.00 from $86.00. Wedbush maintained an outperform rating on October 20, 2026, lifting its target to $110.00 from $100.00. Wall Street analysts currently give the stock a consensus recommendation key of strong_buy with a mean price target of $121.00 based on 10 analyst opinions.

About Disc Medicine

Disc Medicine, Inc. is a clinical-stage biopharmaceutical enterprise focused on discovering and developing new therapies for patients dealing with serious hematologic conditions. The company works on novel treatments designed to address blood disorders and diseases. Institutional interest and analyst updates arrive as the firm prepares for its upcoming earnings update.

Bottom Line

Investors are keeping an eye on the upcoming earnings report scheduled for November 5, 2026, to gauge pipeline progress. Future regulatory updates and institutional filings will provide further clarity on how large funds position themselves in the stock.